Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin

• Status: Completed
• Trial end date: 1997-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Catania
• Treatments: Acetylcarnitine

Criteria

Inclusion Criteria:

• workers who were 18 years of age or older

• Workers who were infected by HCV and had a quantifiable serum HCV RNA level (as determined by polimerase chain reaction, COBAS AmpliPrep/COBAS TaqMan - ROCHE)

• Cirrhotic workers with a Child-Pugh score less than 7

Exclusion Criteria:

• workers who had other liver diseases

• cancer

• severe jaundice

• pulmonary and renal chronic diseases,

• prostatic diseases

• autoimmune diseases

• diabetes mellitus

• decompensated cirrhosis

• pregnancy

• cardiopathy

• hemoglobinopathies

• hemocromatosis

• major depression

• severe psychiatric pathological conditions